Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

Agustin L GonzalezEye & Vision, Richardson, TX 75082, USA, [email protected]Correspondence[email protected]

Pages 2079-2085 | Published online: 16 Oct 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

NicholsJJWillcoxMDBronAJThe TFOS International Workshop on Contact Lens Discomfort: executive summaryInvest Ophthalmol Vis Sci20135411TFOS7TFOS1324058135
PubMed Web of Science ®Google Scholar
NicholsJJJonesLNelsonJDThe TFOS International Workshop on Contact Lens Discomfort: introductionInvest Ophthalmol Vis Sci20135411TFOS1TFOS624058136
PubMed Web of Science ®Google Scholar
NicholsKKRedfernRLJacobJTThe TFOS International Workshop on Contact Lens Discomfort: report of the definition and classification subcommitteeInvest Ophthalmol Vis Sci20135411TFOS14TFOS1924058134
PubMed Web of Science ®Google Scholar
CraigJPWillcoxMDArgüesoPThe TFOS International Workshop on Contact Lens Discomfort: report of the contact lens interactions with the tear film subcommitteeInvest Ophthalmol Vis Sci20135411TFOS123TFOS15624058139
PubMed Web of Science ®Google Scholar
DumbletonKCafferyBDogruMThe TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on epidemiologyInvest Ophthalmol Vis Sci20135411TFOS20TFOS3624058130
PubMed Web of Science ®Google Scholar
EfronNJonesLBronAJThe TFOS International Workshop on Contact Lens Discomfort: report of the contact lens interactions with the ocular surface and adnexa subcommitteeInvest Ophthalmol Vis Sci20135411TFOS98TFOS12224058133
PubMed Web of Science ®Google Scholar
FoulksGChalmersRKeirNThe TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on clinical trial design and outcomesInvest Ophthalmol Vis Sci20135411TFOS157TFOS18324058132
PubMed Web of Science ®Google Scholar
JonesLBrennanNAGonzález-MéijomeJThe TFOS International Workshop on Contact Lens Discomfort: report of the contact lens materials, design, and care subcommitteeInvest Ophthalmol Vis Sci20135411TFOS37TFOS7024058138
PubMed Web of Science ®Google Scholar
PapasEBCiolinoJBJacobsDThe TFOS International Workshop on Contact Lens Discomfort: report of the management and therapy subcommitteeInvest Ophthalmol Vis Sci20135411TFOS183TFOS20324058131
PubMed Web of Science ®Google Scholar
StapletonFMarfurtCGolebiowskiBThe TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on neurobiologyInvest Ophthalmol Vis Sci20135411TFOS71TFOS9724058137
PubMed Web of Science ®Google Scholar
SunYZhangRGadekTRO’NeillCAPearlmanECorneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)J Ocul Pharmacol Ther201329439540223215542
PubMed Web of Science ®Google Scholar
PerezVLPflugfelderSCZhangSShojaeiAHaqueRLifitegrastHRLifitegrast, a novel integrin antagonist for treatment of dry eye diseaseOcul Surf201614220721526807723
PubMed Web of Science ®Google Scholar
SembaCPGadekTRDevelopment of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye diseaseClin Ophthalmol2016101083109427354762
PubMed Web of Science ®Google Scholar
PflugfelderSCSternMZhangSShojaeiALFA-1/ICAM-1 Interaction as a therapeutic target in dry eye diseaseJ Ocul Pharmacol Ther201733151227906544
PubMed Web of Science ®Google Scholar
DonnenfeldEDKarpeckiPMMajmudarPASafety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled StudyCornea201635674174827055211
PubMed Web of Science ®Google Scholar
HollandEJLuchsJKarpeckiPMLifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)Ophthalmology20171241536028079022
PubMed Web of Science ®Google Scholar
SembaCPSwearingenDSmithVLSafety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adultsJ Ocul Pharmacol Ther20112719910420334535
PubMed Web of Science ®Google Scholar
HollandEJWhitleyWOSallKLifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trialsCurr Med Res Opin201617
PubMed Web of Science ®Google Scholar
NicholsKKDonnenfeldEDKarpeckiPMSafety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye diseaseEur J Ophthalmol2018 1120672118791936
Web of Science ®Google Scholar
NicholsKKHollandEToyosMMOcular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trialClin Ophthalmol20181226327029440868
PubMed Web of Science ®Google Scholar
PatonDMLifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye diseaseDrugs Today201652948549327883115
PubMed Web of Science ®Google Scholar
GodinMRGuptaPKLifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapyClin Ophthalmol20171195195728579745
PubMed Web of Science ®Google Scholar
De PazCJGonzalezALNgoCSIDRE: Symptomatic improvement of dry eye studyClin Optom201794954
Web of Science ®Google Scholar
ChalmersRLBegleyCGMoodyKHickson-CurranSBContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performanceOptom Vis Sci201289101435144222960615
PubMed Web of Science ®Google Scholar
ChalmersRLKeayLHickson-CurranSBGleasonWJCutoff score and responsiveness of the 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8) in a Large daily disposable contact lens registryCont Lens Anterior Eye201639534235227131891
PubMed Web of Science ®Google Scholar
EfronNRethinking contact lens discomfortClin Exp Optom201810111329235184
PubMed Web of Science ®Google Scholar
EfronNContact lens wear is intrinsically inflammatoryClin Exp Optom2017100131927806431
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date